Showing results (191-200 of 210) with videos related to

Sort By:
Pageof 21
British Journal of Haematology|November 16, 2022
Characterising the prevalence of overweight and obese status among adults with sickle cell diseaseStephanie O Ibemere, Charity I Oyedeji, Liliana Preiss, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|October 25, 2024
Patient-reported pregnancy loss and maternal complications: Insights from the sickle cell disease implementation consortiumJoacy G Mathias, Rita V Masese, Allison A King, et al.
Blood Advances|May 6, 2021
Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell diseaseAlexis Leonard, Akshay Sharma, Naoya Uchida, et al.
JMIR Research Protocols|May 23, 2020
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation StudyJane S Hankins, Nirmish Shah, Lisa DiMartino, et al.
Cancer Research|December 8, 2020
Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African AncestryYadav Sapkota, Na Qin, Matthew J Ehrhardt, et al.
Frontiers in Pharmacology|January 5, 2026
Hydroxyurea utilization among individuals with sickle cell disease in Tennessee: a pooled analysis of claims dataAyesha Mukhopadhyay, Matthew P Smeltzer, Judy Dudley, et al.
Blood|June 11, 2020
Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell diseaseRuta Brazauskas, Graziana M Scigliuolo, Hai-Lin Wang, et al.
The Lancet. Haematology|September 10, 2019
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort studyMary Eapen, Ruta Brazauskas, Mark C Walters, et al.
American Journal of Hematology|September 29, 2015
Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trialJane S Hankins, Mary Beth McCarville, Angela Rankine-Mullings, et al.
The New England Journal of Medicine|August 30, 2023
CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell DiseaseAkshay Sharma, Jaap-Jan Boelens, Maria Cancio, et al.
Pageof 21